A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 ug/h, 100 ug/h, 150 ug/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart FailUre (ADHF) Within 12 Hours After Hospital Admission (Pulmonary Artery Catheter eg, Swan-Ganz Not Required).

Trial Profile

A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 ug/h, 100 ug/h, 150 ug/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart FailUre (ADHF) Within 12 Hours After Hospital Admission (Pulmonary Artery Catheter eg, Swan-Ganz Not Required).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2014

At a glance

  • Drugs Cinaciguat (Primary)
  • Indications Decompensated heart failure
  • Focus Therapeutic Use
  • Acronyms COMPOSE-EARLY
  • Sponsors Bayer
  • Most Recent Events

    • 25 Feb 2011 Planned end date changed from 1 Sep 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 25 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top